Barclays PLC Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Barclays PLC grew its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 55.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 117,395 shares of the company’s stock after buying an additional 42,000 shares during the period. Barclays PLC’s holdings in Zentalis Pharmaceuticals were worth $355,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ZNTL. SG Americas Securities LLC grew its stake in Zentalis Pharmaceuticals by 115.6% in the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after acquiring an additional 30,240 shares during the last quarter. Savant Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $72,000. Ieq Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth approximately $46,000. Anfield Capital Management LLC raised its position in shares of Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock worth $392,000 after purchasing an additional 64,659 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after buying an additional 91,152 shares in the last quarter.

Wall Street Analyst Weigh In

ZNTL has been the subject of a number of analyst reports. Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Wells Fargo & Company cut their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Down 2.4 %

ZNTL stock opened at $1.23 on Friday. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.24. The company has a market cap of $88.50 million, a P/E ratio of -0.49 and a beta of 1.81. The business has a fifty day moving average of $1.50 and a 200-day moving average of $2.38.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. As a group, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers purchased 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The stock was acquired at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the purchase, the director now owns 281,192 shares in the company, valued at approximately $393,668.80. This represents a 8.07 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.60% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.